ObesityExercise and fitnessGeneticsWeight loss
What this study is
The main objective is to examine DNA hypomethylation as an underlying mechanism for the increased production of inflammatory cytokines and the impaired vascular function in obese individuals and as a potential target for nonpharmacological preventive/therapeutic interventions such as aerobic exercise.
What's being tested
- Exercise training
Intervention · OTHER
Twelve weeks of aerobic exercise training
Study details
- Official title
- DNA Methylation and Vascular Function in Obesity: Role of Exercise and Weight Loss
- Sponsor
- University of Illinois at Chicago
- Conditions
- Obesity · Vascular Dysfunction
- Enrolling
- 80 people
- Starts
- 2019-10-11
- Est. completion
- 2026-08-31
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 50 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- BMI ≥ 35 kg/m2
- Between ages 18-50 years
- Not pregnant
- Approved for a bariatric surgery
You can't join if
- To avoid confounding from other inflammatory conditions individuals with current cancer, heart, kidney or liver disease, gallbladder disease or acute or chronic inflammatory diseases (including rheumatoid arthritis, lupus and other autoimmune diseases and genetic diseases) will be excluded
- Pregnant women will be excluded, as they will not be eligible for bariatric surgery
- Current smokers
- Currently abusing alcohol or drugs
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openUniversity of Illinois at Chicago
Chicago, Illinois, United States
- Abeer M Mohamed, MD, PhD · Contact312-355-8099amahmo4@uic.edu
Recruiting
Study team
Sponsor
University of Illinois at Chicago
Study ID 2017-1125
Principal investigator
Abeer Mohamed, MD, PhD
University of Illinois at Chicago
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.